The evidence for the presence of mammary carcinomaassociated antigens has been reported (Howard & Taylor, 1979; Springer et al., 1979; Sheiks et al., 1979) . Conversely, antibodies present in the serum of patients with mammary carcinoma have also been shown to be reactive with the carcinoma cells (Colcher et al., 1981; Soule et al., 1983) . Accordingly, attempts have been made to utilise lymphocytes from patients with metastatic malignant diseases to produce human monoclonal antibodies by the hybridoma technique (Cote et al., 1983; Haspel et al., 1985; Low et al., 1984; Schlom et al., 1980; Sikora et al., 1981) . In order to generate such human antibodies, lymphocytes were taken from the draining lymph nodes of patients with metastatic mammary carcinoma and fused with nonsecretory variant of mouse myeloma cells to obtain human immunoglobulin secreting hybrids. This paper reports the generation and application of human monoclonal antibodies as probes to identify and characterise antigens which are present at elevated levels in malignant compared with normal mammary epithelia.
Materials and methods

Materials
Aminopterin, thymidine and hypoxanthine were obtained from Sigma Chemicals (St Louis, MO, USA) and polyethylene glycol 1500 from Aldrich Chemical Co. (Milwaukee, WI, USA) . Chromatographically purified human IgM and IgG, rabbit antihuman IgM (M-chain specific), rabbit antihuman IgG (gamma-chain specific), F(ab)'2 fragment of goat antihuman Fab, rabbit antihuman kappa and lambda light chains, mouse IgG and IgM and sheep antimouse immunoglobulins with no cross reactivity to human immunoglobulins were the products of Cappel Laboratories. Tissue culture reagents were purchased from Flow Laboratories CA, USA) and a gamma horse serum from Bio-Cells Laboratory (Carson, CA, USA).
Cell fusion and cloning Portions of axillary lymph nodes from patients with metastatic breast carcinoma were obtained and processed as described previously in order to obtain live human lymphocytes in suspension . The lymphocytes and mouse myeloma cells (M5, a non-secreting and horse serum adapted subline of SP2/OAg 14) were mixed at a ratio of 2.5 to 1, respectively, and fused using 34% (v/v) polyethylene glycol (mol. wt 1,500 daltons) as described previously . The hybrid cells secreting human immunoglobulin with reactivity to breast carcinoma cells in tissue sections were cloned by limiting dilution. Using this procedure, cloning efficiency varied from 29 to 54% (average 44%).
Spent-media from wells containing hybrid-cells were assayed for the presence of human IgG or IgM by solid phase enzyme-linked immunosorbent assay (ELISA) as described previously .
Production and purification of human monoclonal antibodies The human-mouse hybrid clones, designated as HMA-29 (IgG1 antibody), (IgG2 antibody), selected on the basis of production of antibodies with strong reactivity to mammary carcinoma cells in tissue sections, were injected intraperitoneally into Balb/C nude mice which had been primed with pristane 3 weeks earlier. Two to three weeks later, ascites fluid was harvested from the mice and clarified by centrifugation at 12,000g and 4°C for 15min. The immunoglobulin from ascites fluid was purified as described previously . The purified antibodies were conjugated with biotinyl-N-hydroxysuccinimide ester as described previously .
Preparation of tissue sections Uninvolved and malignant human tissues were obtained from the surgical pathology files of the University of Southern California/Los Angeles County Medical Center. Tissues used were either frozen in liquid nitrogen or fixed in 10% buffered-formalin. The fixed paraffin embedded tissue was sectioned at 5,um in thickness. Representative tissuesections were stained with Haematoxylin and Eosin to confirm the diagnosis before immunoperoxidase staining.
Comparison of epitopes recognised by human MAbs
To determine whether the presently generated two antibodies and those generated previously, termed CA-27 (25) and JD-39 (22) , recognise similar or different epitopes, blocking assays using immunohistological techniques were performed as described previously . The antibodies CA-27 (25) or JD-39 (22) were generated previously in a similar manner. The ability of these antibodies to discriminate malignant from normal cells in breast tissues was not as significant as those presently prepared, HMA-29 and HMA-31.
Immunocytochemical localisation of tissue antigens
The four-layer unlabelled antibody peroxidaseantiperoxidase, PAP, and an avidin-biotin-peroxidase complex, ABC, methods were used for localising tissue antigens with the human monoclonal antibodies .
PAP method of staining This method of staining was employed during the initial period of screening. Human monoclonal antibodies produced by hybrids in tissue-culture-medium were tested for their ability to bind to antigens in histological sections of breast tissue. The tumour tissues used in the primary screening were obtained from the patients who acted as sources of lymphocytes for fusion. Rabbit antihuman IgG or IgM and swine antirabbit antibody were used as the 'link' or 'bridge antibodies' between the human monoclonal antibody (primary) and rabbit peroxidase-antiperoxidase (PAP) complex. Controls included the replacement of primary antibody by an irrelevant human monoclonal antibody to Hodgkin's cells. (Antibody secreted by hybrid that was obtained by fusing mouse myeloma cells with lymphocytes of lymph node from patients with Hodgkin's disease. The antibody showed strong reactivity with Reed-Stemnberg cell (manuscipt in preparation).) The tissue sections were incubated with each antibody in an appropriate dilution for 60 min at room temperature. Following each incubation period, the sections were washed with PBS for 15min. The remainder of the procedures was as described previously Bloom & Richardson (1975 Absorption of biotinylated human monoclonal antibodies with known antigens The biotinylated antibodies, HMA-29 or HMA-3 1 (1 mg ml -1) were separately incubated overnight at 4°C with 1Omg protein preparation from human erythrocytes, lymphocyte, milk-fat-globule membrane (Imam et al., 1981 (Imam et al., , 1982 , keratins (Sun & Green, 1978) , the detergent extract of unlabelled MCF7 cell lysates, mammary carcinoma tissue or 1 mg of carcinoembryonic antigen (CEA) immobilised to Sepharose 4B. The procedure of preparing the extract of unlabelled cell lysate was the same as described below for the metabolically labelled cells. Following incubation, the solutions were centrifuged at l00,OOOg and 4°C for 30min. The supernatants containing absorbed antibodies were removed and subsequently applied to tissue sections for immunostaining analysis.
Characterisation of the epitope recognised by human MAbs Investigation was conducted to determine whether the human monoclonal antibodies were directed to the protein and/or the carbohydrate portion of antigens recognised by the antibodies as described below.
Treatment with endo-f3-N-acetylglycosaminidase H To monitor the cleavage of antigens recognised by or HMA-31 with endo-fl-N-acetylglucosaminidase H, 0.25pg protein of MCF7 cell line extract in I00pl of 0.1 M sodium citrate buffer, pH5.5, containing 50mu of the enzyme were incubated at 37°C for 18h as described by Tarentino et al. (1974) . Following incubation, the reaction mixture was mixed with an equal volume of cold 12.5% (w/v) trichloroacetic acid (TCA) for 15 min at 4°C. The mixture was centrifuged at 12,000g and 4°C for 15min, and the supernatant was removed and dialysed against several changes of PBS at 4°C. The pellet was dissolved in 100 !l of PBS and dialysed. To ensure a complete precipitation, an appropriate control containing only the antigen in the absence of the enzyme was included.
Treatment with pepsin Two hundred and fifty micrograms of protein from MCF7 cell line extract was dissolved in 100I 1 of 0.07M sodium acetate buffer, pH4.0, containing 0.05MNaCl and 15jg of pepsin, and the reaction mixture was incubated at 37°C in a water-bath for 18h. At the end of the enzymic digestion period, the pH of the solution was adjusted to 8 with 1 N NaOH and was dialysed against several changes of PBS.
Metabolic labelling of cells and preparation of cell lysate Mammary carcinoma cell line, MCF7, and melanoma cell line, M 17, were grown as monolayer cultures in 75 mm2 tissue culture flasks and intrinsically labelled when cultures were still subconfluent. The cells were labelled for 24-48 h with either 2 mCi of 3H-leucine (110 Ci mmol -1) or 10 mCi of 32P-phosphate (carrier-free) per flask of leucine or phosphate-free DME medium respectively. Following incubation, the cells were washed three times and lysed with 0.05 M Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl, 0.5% (v/v) Nonidet P-40 (NP-40), 0.5% (w/v) sodium deoxy-cholate, 1 mM phenylmethylsulphonyl fluoride and 0.5 mM chloromethyl-L-(2-phenyl-l-p-toluenesulphosnamide) ethyl ketone on ice for 15 min. The lysates were centrifuged at 40,000g and 4°C for 20 min. The supernatants containing detergent-solubilised materials were subsequently used for immunoprecipitation.
Immunoprecipitation of extracts of radiolabelled cells with human monoclonal antibodies The radiolabelled cell lysates (approximately 400 ng of protein containing 5 x 107 c.p.m.) were mixed with 100 p1 of either a specific human MAb (1.Omgml-1) or an irrelevant human MAb generated by fusing lymphocytes from patients with Hodgkin's disease. The latter antibody served as a negative control. The mixtures were incubated at 4°C for 16h. Following the incubation, a 100I 1 suspension of Sepharose 4B conjugated to goat antihuman IgG as described above was added to each reaction mixture. The samples were incubated for a further period of 60min and centrifuged at 5,000g for 5 min. Following the removal of supernatant by aspiration, the pellet was washed five times with 0.05 M NaCl, 1.0% (w/v) ovalbumin and 0.2% (v/v) NP-40 to remove any non-specifically bound radioactivity. No radioactivity was detectable in the supernatant of the fifth wash.
SDS-Polyacrylamide gel electrophoresis
The materials immunoprecipitated with the human MAbs were subsequently analysed by SDS-polyacrylamide gel electrophoresis. The washed pellets were solubilised in 0.05M Tris-HCI buffer, pH 6.8, containing SDS and 2-mercaptoethanol, boiled for 5min and centrifuged at 8,000g for 5 min at room temperature. The supernatants were subjected to electrophoresis in 7.5% polyacrylamide slab gels in the presence of SDS by the method of Laemmli (1970 aNumber of wells with growing hybrids with >0.5 yg immunoglobulin per ml of spent medium. bFollowing immunohistological screening for specificity, hydrids from one of each of these wells were selected and cloned (see Table II ). aHybrids from six immunoglobulin positive wells (see Table I and column 4, one from each fusion) were selected, cloned and plated into two 96-well plates. The parameters of selection for cloning of hybrids were based upon their ability to secrete higher amounts of Ig with strong reactivity to tumour cells in tissue sections more than the Ig produced by the remaining hybrids.
obtained from lymphocytes from patients with metastatic breast carcinomas synthesised human immunoglobulins (Table I) . Hybrids from six immunoglobulin positive wells, one deriving from each fusion (Table I, (Table II) . Of these antibodies, 14IgG (27%) and 51 IgM (54%) showed evidence of reactivity to tumour cells as described above (Table II) . 
Comparison of epitopes recognised by human monoclonal antibodies
The experiments were performed to determine any similarity between epitopes recognised by presently generated human monoclonal antibodies (HMA-29, HMA-31) and previously generated antibodies (CA-27 (25) or JD-39 (22)) . The immunoblocking experiments showed that the antigenic binding sites for antibody HMA-29 were not blocked by antibody HMA-31. Conversely, the reactivity of HMA-31 was not obstructed by antibody HMA-29 (Table  III) . Indeed, the antigens recognised by these antibodies are also different with respect to their molecular weights ( Figure  2, lanes a, b) . Furthermore, the binding activity of HMA-29 and HMA-31 was not blocked by any of the previously generated antibodies CA-27 (25) or JD-39 (22) ( Table III) . The results indicate that two different epitopes are recognised by the antibodies and are not related to epitopes recognised by previously generated antibodies.
Localisation of cellular antigens with human monoclonal antibodies Spent medium from each of the immunoglobulin-producing clones was initially screened for binding activity to tissue sections of autologous breast carcinoma using an indirect immunoperoxidase (PAP) staining technique. The indirect four-layer PAP methods gave some background staining, attributable to detection of endogenous IgM or IgG in breast tissues. Endogenous immunoglobulin sensitivity was more notable while staining for human monoclonal antibodies of IgG class, but did not interefere with the interpretation of staining patterns, which in all cases were assessed with reference to positive and negative controls as described in the methods section. The findings are summarised in Table II (columns 5, 6).
Fourteen IgG and 51 IgM human MAbs showed staining of tumour cells with a variable intensity in all cases of infiltrating ductal carcinoma of the breast (Table II) . Under these conditions, lymphocytes, blood vessels and stromal elements failed to stain. Weak staining of morphologically normal breast epithelial cells present in the same tissue section was observed in some cases. However, the intensity of staining in such cases was much less than for malignant cells (Figure la upon their ability to stain tumour cells more intensely than the remaining 63 antibodies. Subsequently, those two antibodies were generated in large amounts, purified and biotinylated as described under Materials and methods. The intensity and pattern of staining with these conjugated antibodies of the tumour cells in tissue sections using the avidin-biotin (ABC) method was comparable to that of the four-layer PAP method used in the initial stage of the screening. However, the most distinct and significant advantage gained by the direct ABC method over the PAP method was the elimination of background staining (i.e. endogenous immunoglobulin was not detected by the direct ABC method). The staining results of a panel of paraffin sections that included 44 cases of primary mammary carcinomas, three cases of fibroadenoma, three cases of morphologically uninvolved breast, two cases of lactating breast and five cases of metastatic mammary carcinoma cells in regional axillary lymph nodes are summarised in Table IV. Antibody HMA-29 and HMA-31 showed variable staining of tumour cells in 84% and 77% of the primary and the regional metastatic mammary carcinomas respectively. The antigenic heterogeneity of malignant cells was observed (Figure lb) . The lymphocytes and connective tissue elements in the breast section, and lymphocytes in ly'mph nodes, were unreactive with the antibodies. Both antibodies showed variable reactivity with malignant epithelial cells of colon, stomach and lung (Table IV) . The antibodies quantitatively discriminated malignant from normal cells in mammary and extramammary tissue sections whether freshly frozen or formalin-fixed. Control sections in which the monoclonal antibodies were replaced by equivalent amounts of human IgG or IgM (in the case of the four-layer PAP method during initial screening of the antibodies) or an irrelevant biotinylated human monoclonal antibody (generated in a similar manner to Hodgkin's cells in the subsequent studies) showed no staining.
Comparison with known antigens
Both antibodies, HMA-29 and HMA-31, showed no change in their pattern of reactivity with the cells in tissue sections following adsorption with carcinoembryonic antigen (CEA), erythrocyte, lymphocyte, milk-fat-globule membrane (MFGM) or keratins, suggesting that the epitopes recognised by these antibodies are dissimilar to those present in the absorbents. By contrast, absorption of the antibodies with detergent extracts of MCF7 cell lysate and mammary carcinoma tissue completely abolished staining of tumour cells in tissue sections, attesting to the specificity of the reaction.
The nature of epitopes recognised by human monoclonal antibodies The antibodies absorbed with TCA-precipitable fraction, resulting from treatment of the antigens with endo-f,-Nacetylglucosaminidase H, led to a complete elimination of immunostaining of cells. The absorption of the antibodies with the TCA-soluble fraction of the endoglycosidasetreatment (supernatants) or TCA-precipitable fractions from pepsin treatment of the antigen had no effect on the intensity of the immunostaining. The results suggest that the antibodies recognised epitopes which are expressed on the protein domain of their corresponding antigen.
Immunoprecipitation and electrophoretic analysis of radiolabelled antigens recognised by human MAbs 3H-Leucine or 32P-phosphate labelled cells from a mammary carcinoma cell line (MCF7) and a cutaneous malignant melanoma cell line (M17) were used to study the nature and range of expression of antigens recognised by human MAbs. The immunoprecipitation experiments, using the NP 40-deoxycholate solubilised lysates of intrinsically labelled components of MCF7, revealed that the antigens recognised by antibodies HMA-29 and HMA-31 represented 0.008% and 0.01% respectively of the total lysate. The results suggest that the target antigens are minor components of the MCF7 cell line. Autoradiographical analysis of 3H-leucine labelled MCF7 lysate on SDS-polyacrylamide gel electrophoresis showed one component with with an apparent molecular weight of 29,000 daltons and two components with HMA-31, with apparent molecular weights of 31,000 and 34,000 daltons ( Figure 2, lanes a, b) (Figure 2, lanes a, g) . The antibody HMA-31 failed to immunoprecipitate any detectable component from 32P-labelled MCF7 lysate (Figure 2 , lane h), and none of the antibodies gave detectable immunoprecipitation with lysates of 3H-leucine labelled melanoma cells (Figure 2, lanes d, e) .
Conversely, cell lysates of both the mammary and melanoma cell lines were non-reactive with an irrelevant human MAb that was generated to Hodgkin's disease (Figure 2, lanes c, f, i) .
To investigate the structural relationship of the 29, 31 and 34 kilodalton protein components, 3H-leucine or 32P-phosphate labelled immunoprecipitates were analysed under both non-reducing and reducing conditions by SDSpolyacrylamide gel electrophoresis. Under both conditions, patterns of migration of these components remained similar, suggesting the absence of disulphide bonds between these molecules (data not shown).
Discussion
This study has shown that human-mouse hybridomas can be obtained by fusing murine myeloma cells with lymphocytes from the lymph nodes of patients with metastatic mammary carcinomas. The inter-species hybrids were initially unstable for immunoglobulin production, but could be made stable in culture by the following manoeuvres. Repeated cloning formed a separation of immunoglobulin secreting hybrids from non-secreting hybrids: the removal of non-secretory hybrids appears to be crucial as they tend to proliferate at a higher rate and eventually overgrow those hybrids actively secreting immunoglobulins. In order to detect the development of non-secreting hybrids, the level of immunoglobulin production was constantly monitored, and when any decrease was detected, the hybrids were immediately recloned. The hybrid clones were frozen in several aliquots, and were thawed and propagated for 2-3 weeks when needed. Sufficient numbers of hybrid cells were obtained for injection into nude mice in order to generate large amounts of human monoclonal antibodies in ascites-fluid. Taking into consideration all these factors, one can successfully obtain inter-species hybrids that are stable in continuing to secrete human immunoglobulins.
Anticipating the presence of only small amounts of human MAbs in spent medium, an indirect four-layered peroxidaseantiperoxidase (PAP) method (Narikito & Taylor, 1982) One significant advantage of immunohistological screening over other methods is that it provides information not only of positivity against a particular cell type, but also of specificity, in that differential staining of the various cell types present in the test sections may be observed. This permits elimination of those antibodies which react with many cells or tissue elements. For further tests of specificity and patterns of reactivity of the selected human MAbs against a variety of tissue specimens, a direct immunoperoxidase method was adopted, utilising biotinylated primary antibody and avidin-biotin-peroxidase complex (ABC) system. This direct approach eliminates the detection of endogenous human immunoglobulin, without compromising detection of binding of the human MAbs to tissue antigens. However, direct biotinylation is not feasible for use in the initial screening of supernatants due to the sheer number of wells that must be assayed.
Both antibodies (designated HMA-29 and HMA-31) in a range of 0.2-2 pg ml-per tissue section showed strong binding with malignant and very weak binding with normal mammary epithelial cells in both frozen or formalin-fixed tissue sections (Figure 1 ). Reactivity of both antibodies appeared to be mostly cytoplasmic at the light microscopical level. The immunoelectron microscopical examination may facilitate the specific localisation of the target antigens. Low intensity of staining of normal mammary epithelial cells was also observed, suggesting the presence of smaller amounts of antigen(s) in normal cells. The intensity of the staining in such instances was much weaker than that observed with malignant cells. Approximately 70-80% of the malignant cells in frozen or formalin-fixed tissue sections at their primary sites in any given tissue section showed reactivity with the antibodies, suggesting antigenic heterogeneity in the population of primary tumour cells (Table IV) .
The antigens detected by antibodies HMA-29 and HMA-31 were not unique to mammary epithelial cells as revealed by the reactivity of these antibodies with malignant epithelial cells of colon, stomach and lung. However, the demonstration of tissue antigens by immunostaining yields little indication of the nature of the antigens in these different sites. Therefore, isolation and biochemical characterisation of target antigens from the above sources warrants subsequent studies.
The immunoprecipitation experiments revealed that the antigens recognised by the antibodies represent minor constituents of MCF7 cell line. Consequently, the use of cell lysates containing high radioactive counts became essential in visualising the target antigens. As a result, the goat antihuman IgG antibodies, which were used as the second antibodies during the immunoprecipitation, were immobilised to bisoxirane instead of cyanogen bromide-activated Sepharose 4B as the former yields less non-specific absorption of proteins (Murphy et al., 1976; Sundberg, 1974) . Two protein components immunoprecipitated by antibody HMA-31 were observed on the gels under non-reducing conditions, suggesting that these components are not disulphide-linked (not illustrated). Furthermore, epitopes recognised by these and previously generated antibodies are not similar as suggested by the immunocompetition experiments (Table III) .
Finally, concurrent to the observation of elevated levels of cellular antigens recognised by allogenic immune response, elevated expression of several cellular oncogenes has been described in patients with metastatic mammary carcinomas (Slamon et al., 1984) and other malignant diseases (Erikson et al., 1983; Gallick et al., 1985; Giallongo et al., 1983; Heighway & Hasleton, 1986; Slamon et al., 1984; Stewart et al., 1986) . It is conceivable that the antigens detected in autologous malignant cells by human monoclonal antibodies may be related to growth factors or their receptors, some of which have been found to be oncogene products. Human monoclonal antibodies may, therefore, be useful probes to determine functional aspects of these antigens. Furthermore, these antibodies, compared with xenogenic monoclonal antibodies, are potentially useful probes for radiolocalisation and immunotherapy of patients with mammary carcinomas.
